Publication | Open Access
Neoadjuvant Camrelizumab Plus Platinum-Based Chemotherapy vs Chemotherapy Alone for Chinese Patients With Resectable Stage IIIA or IIIB (T3N2) Non–Small Cell Lung Cancer
85
Citations
16
References
2023
Year
ClinicalTrials.gov Identifier: NCT04338620.
| Year | Citations | |
|---|---|---|
Page 1
Page 1